WFSBP Programme 2015

80 / 112

78
WFSBP 2015
Scientific Programme | Thursday, 18 June 2015
S-59-003
Proinflammatory cytokines and oxidative stress decreases
the dopamine precursor tyrosine uptake in human skin
fibroblasts
Ravi Vumma, Sweden
J. Johansson, N. Venizelos
S-59-004
A comparative genomic meta-analysis study focused on
genes and mechanisms involved in amino acid transport
in schizophrenic and bipolar disorder patients
Fragiskos Kolisis, Greece
N. Venizelos, A. Chatziioannou, O. Papadodima, M. Logotheti
T24: Neurophysiology
S-60 Symposium
15:00–16:30 MC 2 Room
Neural oscillations: Translational research in psychiatry
Chair: Toshiaki Onitsuka, Japan
Co-Chair: Robert McCarley, USA
S-60-001
Neural oscillations: Optogenetic studies in mice
Robert McCarley, USA
T. Kim, S. Thankachan, J. McKenna, J. McNally, J. H. Choi,
R. Strecker, R. Basheer, R. Brown, C. Yang
S-60-002
Findings of auditory steady-state responses in psychiatric
disorders
Toshiaki Onitsuka, Japan
S-60-003
Neural dynamics with simultaneous EEG and fMRI mea­
surement
Hiroaki Mizuhara, Japan
S-60-004
NMDA-R hypofunctioning and dysregulated high-frequency
oscillations in schizophrenia
Peter Uhlhaas, United Kingdom
T10: Depression: Basic / Clinical
S-61 Symposium
15:00–16:30 Kokkali Room
A paradigm shift in studies of affective disorders
Chair: Takashi Kudo, Japan
S-61-001
Looking for biomarkers of depressive behavior in rats in
order to promote closed loop therapeutic interventions
Christine Winter, Germany
S-61-002
Brain fatty acid metabolism: A promising starting point
for the translational research of affective and related psy-
chiatric disorders
Yoshitaka Tatebayashi, Japan
S-61-003
Role of immune-to-brain interactions in the pathophysi-
ology of depression
Lucile Capuron, France
S-61-004
Role of sigma 1 receptor in the pathophysiology of de-
pression
Takashi Kudo, Japan
T1: Addictive Disorders
TG-07 WFSBP Treatment Guidelines
11:00–12:30 MC 3 Room
Task Force on Addictive Disorders: Biological treatments
of substance use disorders: Recent developments and
findings
Chair: Michael Soyka, Switzerland
Co-Chair: Siegfried Kasper, Austria
TG-07-001
New developments in pharmacotreatment of opioid de-
pendence
Michael Soyka, Switzerland
TG-07-002
New evidence-based treatment guidelines for alcohol use
disorders
Karl Mann, Germany
TG-07-003
Genetics and pharmacogenetics of alcoholism: Recent
developments
Victor Hesselbrock, USA
T4: Anxiety Disorders: Basic/ Clinical
D-03 Debate
11:00–12:30 Trianti Hall
Should anxiety disorders be treated with medication?
Chair: Martin Hatzinger, Switzerland
Co-Chair: Ladislav Hosak, Czech Republic
Proponent: Michel Bourin, France
Opponent: Borwin Bandelow, Germany